Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

Abstract The DNA-damaging agent Gemcitabine (GEM) is a first-line treatment for pancreatic cancer, but chemoresistance is frequently observed. Several clinical trials investigate the efficacy of GEM in combination with targeted drugs, including kinase inhibitors, but the experimental evidence for su...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefanie Höfer, Larissa Frasch, Sarah Brajkovic, Kerstin Putzker, Joe Lewis, Hendrik Schürmann, Valentina Leone, Amirhossein Sakhteman, Matthew The, Florian P Bayer, Julian Müller, Firas Hamood, Jens T Siveke, Maximilian Reichert, Bernhard Kuster
Format: Article
Language:English
Published: Springer Nature 2025-01-01
Series:Molecular Systems Biology
Subjects:
Pancreatic Cancer
Kinase Inhibitors
Drug Combination Screening
Phosphoproteomics
DNA Damage Response
Online Access:https://doi.org/10.1038/s44320-025-00085-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44320-025-00085-6

Similar Items